Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.76 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | BCR | P11274 | 2/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652444 | 0.87 | SRC (0.89) | SRCABL1BCRGAKEGFR | |
| SCHEMBL6182533 | 0.87 | SRC (1.00) | SRCABL1BCRGAKEGFR | |
| SCHEMBL6184514 | 0.85 | SRC (1.00) | SRCABL1GAKEGFR | |
| SCHEMBL6185211 | 0.83 | SRC (0.84) | SRCABL1BCREGFR | |
| SCHEMBL6184168 | 0.83 | SRC (1.00) | SRCABL1BCREGFR | |
| SCHEMBL6182900 | 0.82 | SRC (0.93) | SRCABL1BCRGAKEGFR | |
| SCHEMBL6183244 | 0.82 | SRC (0.85) | SRCABL1BCR | |
| SCHEMBL6182389 | 0.81 | SRC (0.91) | SRCABL1BCRGAKEGFR | |
| SCHEMBL4741681 | 0.80 | SRC (0.66) | SRCABL1BCREGFR | |
| SCHEMBL6185380 | 0.80 | SRC (0.72) | SRCABL1BCREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2005115145-A2 | QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS | WYETH (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | SRC 960/4885ABL1 64/4885BCR 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.